secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0000950170-21-003931
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics Q3 2021 net loss $10.0M; CP101 Phase 2 shows 80.3% cure rate
-------------------------------------------------------------------------------

- Net loss of $10.0M for Q3 2021 (vs. $10.1M loss in Q3 2020); R&D expenses increased to $15.5M from $9.0M.
- CP101 Phase 2 open-label trial: 80.3% sustained clinical cure at 8 weeks, 78.8% at 24 weeks in recurrent CDI.
- Initiated enrollment in PRISM4 Phase 3 trial of CP101; topline data expected H1 2023.
- Cash and equivalents $149.2M as of Sept 30, 2021; expected to fund operations into mid-2023.
- CMO Zain Kassam stepped down; Debra Silberg named interim CMO; Marc Blaustein joined as COO; Al Hamood added to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017021003931/0000950170-21-003931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017021003931/fnch-20211110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-003931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer